Cellular immunotherapy for plasma cell myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-05-06

AUTHORS

A L Garfall, D T Vogl, B M Weiss, E A Stadtmauer

ABSTRACT

Allogeneic hematopoietic cell transplantation for plasma cell myeloma can lead to graft-vs-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies seek to induce more specific, reliable and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Strategies under development include infusion of vaccine-primed and ex vivo expanded/costimulated autologous T cells after high-dose melphalan, genetic engineering of autologous T cells with receptors for myeloma-specific epitopes, administration of DC/plasma cell fusions and administration expanded marrow-infiltrating lymphocytes. In addition, novel immunomodulatory drugs such as inhibitors of the programmed death-1 T cell regulatory pathway may synergize with cellular immunotherapies. More... »

PAGES

1377-1386

References to SciGraph publications

  • 2011-09-26. Effect of acute and chronic graft-versus-host disease on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma in BONE MARROW TRANSPLANTATION
  • 2000-03. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids in NATURE MEDICINE
  • 2004-11-08. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC) in BONE MARROW TRANSPLANTATION
  • 2010-10-15. Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases in MODERN PATHOLOGY
  • 1998-01. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies in BONE MARROW TRANSPLANTATION
  • 2012-03-22. Cancer immunotherapy via dendritic cells in NATURE REVIEWS CANCER
  • 2003-05-28. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma in BONE MARROW TRANSPLANTATION
  • 2006-03-13. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma in BONE MARROW TRANSPLANTATION
  • 1999-01. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation in BONE MARROW TRANSPLANTATION
  • 2008-09-11. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells in LEUKEMIA
  • 2012-03-22. The blockade of immune checkpoints in cancer immunotherapy in NATURE REVIEWS CANCER
  • 2003-12-01. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect in BONE MARROW TRANSPLANTATION
  • 2001-11-26. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect in BONE MARROW TRANSPLANTATION
  • 2000-03-01. Smallpox, polio and now a cancer vaccine? in NATURE MEDICINE
  • 2002-01. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection in NATURE MEDICINE
  • 2004-03-25. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma in LEUKEMIA
  • 2006-05-17. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma in BONE MARROW TRANSPLANTATION
  • 2008-09-01. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma in BONE MARROW TRANSPLANTATION
  • 2000-12-13. Donor leukocyte infusions for multiple myeloma in BONE MARROW TRANSPLANTATION
  • 2000-03-13. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion in BONE MARROW TRANSPLANTATION
  • 2003-10-27. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells in BONE MARROW TRANSPLANTATION
  • 2008-10-08. Genetic engineering of T cells for adoptive immunotherapy in IMMUNOLOGIC RESEARCH
  • 2002-07-01. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia in LEUKEMIA
  • 2005-10-16. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/bmt.2013.54

    DOI

    http://dx.doi.org/10.1038/bmt.2013.54

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003558291

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/23645169


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematopoietic Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy, Adoptive", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multiple Myeloma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Randomized Controlled Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.25879.31", 
              "name": [
                "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garfall", 
            "givenName": "A L", 
            "id": "sg:person.01125212546.87", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125212546.87"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.25879.31", 
              "name": [
                "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vogl", 
            "givenName": "D T", 
            "id": "sg:person.01154427341.76", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154427341.76"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.25879.31", 
              "name": [
                "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Weiss", 
            "givenName": "B M", 
            "id": "sg:person.01356555461.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356555461.61"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.25879.31", 
              "name": [
                "Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stadtmauer", 
            "givenName": "E A", 
            "id": "sg:person.01044042041.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044042041.97"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bmt.1702187", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049549300", 
              "https://doi.org/10.1038/sj.bmt.1702187"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1705342", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047200252", 
              "https://doi.org/10.1038/sj.bmt.1705342"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704050", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041964316", 
              "https://doi.org/10.1038/sj.bmt.1704050"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1701546", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010266260", 
              "https://doi.org/10.1038/sj.bmt.1701546"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2008.295", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007359485", 
              "https://doi.org/10.1038/bmt.2008.295"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2011.192", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009911180", 
              "https://doi.org/10.1038/bmt.2011.192"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2008.247", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016405144", 
              "https://doi.org/10.1038/leu.2008.247"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/modpathol.2010.163", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037108867", 
              "https://doi.org/10.1038/modpathol.2010.163"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047946992", 
              "https://doi.org/10.1038/nrc3239"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1310", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006907184", 
              "https://doi.org/10.1038/nm1310"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2402503", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016584041", 
              "https://doi.org/10.1038/sj.leu.2402503"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0102-47", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018873794", 
              "https://doi.org/10.1038/nm0102-47"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/73193", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021964373", 
              "https://doi.org/10.1038/73193"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12026-008-8057-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031134227", 
              "https://doi.org/10.1007/s12026-008-8057-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704756", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006339769", 
              "https://doi.org/10.1038/sj.bmt.1704756"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704289", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052066147", 
              "https://doi.org/10.1038/sj.bmt.1704289"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1702685", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020908900", 
              "https://doi.org/10.1038/sj.bmt.1702685"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3258", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036173964", 
              "https://doi.org/10.1038/nrc3258"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1703253", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039030248", 
              "https://doi.org/10.1038/sj.bmt.1703253"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/73082", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052039172", 
              "https://doi.org/10.1038/73082"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1701037", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028910700", 
              "https://doi.org/10.1038/sj.bmt.1701037"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704317", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004709499", 
              "https://doi.org/10.1038/sj.bmt.1704317"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1705373", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047732682", 
              "https://doi.org/10.1038/sj.bmt.1705373"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403341", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012432553", 
              "https://doi.org/10.1038/sj.leu.2403341"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2013-05-06", 
        "datePublishedReg": "2013-05-06", 
        "description": "Allogeneic hematopoietic cell transplantation for plasma cell myeloma can lead to graft-vs-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies seek to induce more specific, reliable and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Strategies under development include infusion of vaccine-primed and ex vivo expanded/costimulated autologous T cells after high-dose melphalan, genetic engineering of autologous T cells with receptors for myeloma-specific epitopes, administration of DC/plasma cell fusions and administration expanded marrow-infiltrating lymphocytes. In addition, novel immunomodulatory drugs such as inhibitors of the programmed death-1 T cell regulatory pathway may synergize with cellular immunotherapies.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/bmt.2013.54", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2682634", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1096890", 
            "issn": [
              "0268-3369", 
              "1476-5365"
            ], 
            "name": "Bone Marrow Transplantation", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "48"
          }
        ], 
        "keywords": [
          "plasma cell myeloma", 
          "cellular immunotherapy", 
          "cell myeloma", 
          "high-dose melphalan", 
          "marrow-infiltrating lymphocytes", 
          "treatment-related risks", 
          "hematopoietic cell transplantation", 
          "long-term survivorship", 
          "novel immunomodulatory drug", 
          "allogeneic transplantation", 
          "immunomodulatory drugs", 
          "cell transplantation", 
          "immune response", 
          "limited efficacy", 
          "immunotherapy", 
          "ex vivo", 
          "cell regulatory pathways", 
          "transplantation", 
          "myeloma", 
          "administration", 
          "widespread use", 
          "cell fusion", 
          "cells", 
          "melphalan", 
          "infusion", 
          "lymphocytes", 
          "immunity", 
          "regulatory pathways", 
          "receptors", 
          "efficacy", 
          "drugs", 
          "epitopes", 
          "risk", 
          "vivo", 
          "inhibitors", 
          "toxicity", 
          "response", 
          "pathway", 
          "survivorship", 
          "use", 
          "addition", 
          "development", 
          "strategies", 
          "fusion", 
          "genetic engineering", 
          "engineering", 
          "myeloma immunity", 
          "potent antimyeloma immune responses", 
          "antimyeloma immune responses", 
          "less treatment-related risk", 
          "myeloma-specific epitopes", 
          "DC/plasma cell fusions", 
          "plasma cell fusions", 
          "death-1 T cell regulatory pathway", 
          "T cell regulatory pathway"
        ], 
        "name": "Cellular immunotherapy for plasma cell myeloma", 
        "pagination": "1377-1386", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003558291"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/bmt.2013.54"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "23645169"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/bmt.2013.54", 
          "https://app.dimensions.ai/details/publication/pub.1003558291"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_613.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/bmt.2013.54"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bmt.2013.54'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bmt.2013.54'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bmt.2013.54'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bmt.2013.54'


     

    This table displays all metadata directly associated to this object as RDF triples.

    260 TRIPLES      22 PREDICATES      111 URIs      79 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/bmt.2013.54 schema:about N468d617236474502930b04d05e8e24a8
    2 N475e1c95a4944094aaee12f68e6d48a3
    3 N5311d60a53874a6b965365d7857f3160
    4 N67f468597c4a48c3b05d3b071ac1221f
    5 N925e63036a72456298f19f2d0046b326
    6 Nd9ffb245adfc45c0b8fe542560ebd09b
    7 anzsrc-for:11
    8 anzsrc-for:1107
    9 schema:author Nd0659a70cb69417bbcc65e6b4bc0fd61
    10 schema:citation sg:pub.10.1007/s12026-008-8057-6
    11 sg:pub.10.1038/73082
    12 sg:pub.10.1038/73193
    13 sg:pub.10.1038/bmt.2008.295
    14 sg:pub.10.1038/bmt.2011.192
    15 sg:pub.10.1038/leu.2008.247
    16 sg:pub.10.1038/modpathol.2010.163
    17 sg:pub.10.1038/nm0102-47
    18 sg:pub.10.1038/nm1310
    19 sg:pub.10.1038/nrc3239
    20 sg:pub.10.1038/nrc3258
    21 sg:pub.10.1038/sj.bmt.1701037
    22 sg:pub.10.1038/sj.bmt.1701546
    23 sg:pub.10.1038/sj.bmt.1702187
    24 sg:pub.10.1038/sj.bmt.1702685
    25 sg:pub.10.1038/sj.bmt.1703253
    26 sg:pub.10.1038/sj.bmt.1704050
    27 sg:pub.10.1038/sj.bmt.1704289
    28 sg:pub.10.1038/sj.bmt.1704317
    29 sg:pub.10.1038/sj.bmt.1704756
    30 sg:pub.10.1038/sj.bmt.1705342
    31 sg:pub.10.1038/sj.bmt.1705373
    32 sg:pub.10.1038/sj.leu.2402503
    33 sg:pub.10.1038/sj.leu.2403341
    34 schema:datePublished 2013-05-06
    35 schema:datePublishedReg 2013-05-06
    36 schema:description Allogeneic hematopoietic cell transplantation for plasma cell myeloma can lead to graft-vs-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies seek to induce more specific, reliable and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Strategies under development include infusion of vaccine-primed and ex vivo expanded/costimulated autologous T cells after high-dose melphalan, genetic engineering of autologous T cells with receptors for myeloma-specific epitopes, administration of DC/plasma cell fusions and administration expanded marrow-infiltrating lymphocytes. In addition, novel immunomodulatory drugs such as inhibitors of the programmed death-1 T cell regulatory pathway may synergize with cellular immunotherapies.
    37 schema:genre article
    38 schema:inLanguage en
    39 schema:isAccessibleForFree true
    40 schema:isPartOf N87e69a3024864eb085ac4d3e7766dc9f
    41 Nc678e501d50543f4a9661ee77410fe39
    42 sg:journal.1096890
    43 schema:keywords DC/plasma cell fusions
    44 T cell regulatory pathway
    45 addition
    46 administration
    47 allogeneic transplantation
    48 antimyeloma immune responses
    49 cell fusion
    50 cell myeloma
    51 cell regulatory pathways
    52 cell transplantation
    53 cells
    54 cellular immunotherapy
    55 death-1 T cell regulatory pathway
    56 development
    57 drugs
    58 efficacy
    59 engineering
    60 epitopes
    61 ex vivo
    62 fusion
    63 genetic engineering
    64 hematopoietic cell transplantation
    65 high-dose melphalan
    66 immune response
    67 immunity
    68 immunomodulatory drugs
    69 immunotherapy
    70 infusion
    71 inhibitors
    72 less treatment-related risk
    73 limited efficacy
    74 long-term survivorship
    75 lymphocytes
    76 marrow-infiltrating lymphocytes
    77 melphalan
    78 myeloma
    79 myeloma immunity
    80 myeloma-specific epitopes
    81 novel immunomodulatory drug
    82 pathway
    83 plasma cell fusions
    84 plasma cell myeloma
    85 potent antimyeloma immune responses
    86 receptors
    87 regulatory pathways
    88 response
    89 risk
    90 strategies
    91 survivorship
    92 toxicity
    93 transplantation
    94 treatment-related risks
    95 use
    96 vivo
    97 widespread use
    98 schema:name Cellular immunotherapy for plasma cell myeloma
    99 schema:pagination 1377-1386
    100 schema:productId N60ba2d6db7e04fad9007c1f47440aabd
    101 Na7236ab3d3654f969ddc2aa83803076a
    102 Ndb06e3b8786e4d4aa706026a0c654970
    103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003558291
    104 https://doi.org/10.1038/bmt.2013.54
    105 schema:sdDatePublished 2021-11-01T18:21
    106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    107 schema:sdPublisher Nd96a013cbfb3456c83c80d143565b0aa
    108 schema:url https://doi.org/10.1038/bmt.2013.54
    109 sgo:license sg:explorer/license/
    110 sgo:sdDataset articles
    111 rdf:type schema:ScholarlyArticle
    112 N24f4fce638974e838b605c3327d867a6 rdf:first sg:person.01356555461.61
    113 rdf:rest N56c2adc556854edc999ae47f75b8965b
    114 N468d617236474502930b04d05e8e24a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Immunotherapy, Adoptive
    116 rdf:type schema:DefinedTerm
    117 N475e1c95a4944094aaee12f68e6d48a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Hematopoietic Stem Cell Transplantation
    119 rdf:type schema:DefinedTerm
    120 N5311d60a53874a6b965365d7857f3160 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Survival Analysis
    122 rdf:type schema:DefinedTerm
    123 N56c2adc556854edc999ae47f75b8965b rdf:first sg:person.01044042041.97
    124 rdf:rest rdf:nil
    125 N60ba2d6db7e04fad9007c1f47440aabd schema:name pubmed_id
    126 schema:value 23645169
    127 rdf:type schema:PropertyValue
    128 N67f468597c4a48c3b05d3b071ac1221f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Randomized Controlled Trials as Topic
    130 rdf:type schema:DefinedTerm
    131 N695fd0bd5664424d87a44fc24e68f79e rdf:first sg:person.01154427341.76
    132 rdf:rest N24f4fce638974e838b605c3327d867a6
    133 N87e69a3024864eb085ac4d3e7766dc9f schema:issueNumber 11
    134 rdf:type schema:PublicationIssue
    135 N925e63036a72456298f19f2d0046b326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Multiple Myeloma
    137 rdf:type schema:DefinedTerm
    138 Na7236ab3d3654f969ddc2aa83803076a schema:name dimensions_id
    139 schema:value pub.1003558291
    140 rdf:type schema:PropertyValue
    141 Nc678e501d50543f4a9661ee77410fe39 schema:volumeNumber 48
    142 rdf:type schema:PublicationVolume
    143 Nd0659a70cb69417bbcc65e6b4bc0fd61 rdf:first sg:person.01125212546.87
    144 rdf:rest N695fd0bd5664424d87a44fc24e68f79e
    145 Nd96a013cbfb3456c83c80d143565b0aa schema:name Springer Nature - SN SciGraph project
    146 rdf:type schema:Organization
    147 Nd9ffb245adfc45c0b8fe542560ebd09b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Humans
    149 rdf:type schema:DefinedTerm
    150 Ndb06e3b8786e4d4aa706026a0c654970 schema:name doi
    151 schema:value 10.1038/bmt.2013.54
    152 rdf:type schema:PropertyValue
    153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    154 schema:name Medical and Health Sciences
    155 rdf:type schema:DefinedTerm
    156 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    157 schema:name Immunology
    158 rdf:type schema:DefinedTerm
    159 sg:grant.2682634 http://pending.schema.org/fundedItem sg:pub.10.1038/bmt.2013.54
    160 rdf:type schema:MonetaryGrant
    161 sg:journal.1096890 schema:issn 0268-3369
    162 1476-5365
    163 schema:name Bone Marrow Transplantation
    164 schema:publisher Springer Nature
    165 rdf:type schema:Periodical
    166 sg:person.01044042041.97 schema:affiliation grid-institutes:grid.25879.31
    167 schema:familyName Stadtmauer
    168 schema:givenName E A
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044042041.97
    170 rdf:type schema:Person
    171 sg:person.01125212546.87 schema:affiliation grid-institutes:grid.25879.31
    172 schema:familyName Garfall
    173 schema:givenName A L
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125212546.87
    175 rdf:type schema:Person
    176 sg:person.01154427341.76 schema:affiliation grid-institutes:grid.25879.31
    177 schema:familyName Vogl
    178 schema:givenName D T
    179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154427341.76
    180 rdf:type schema:Person
    181 sg:person.01356555461.61 schema:affiliation grid-institutes:grid.25879.31
    182 schema:familyName Weiss
    183 schema:givenName B M
    184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356555461.61
    185 rdf:type schema:Person
    186 sg:pub.10.1007/s12026-008-8057-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031134227
    187 https://doi.org/10.1007/s12026-008-8057-6
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1038/73082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052039172
    190 https://doi.org/10.1038/73082
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1038/73193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021964373
    193 https://doi.org/10.1038/73193
    194 rdf:type schema:CreativeWork
    195 sg:pub.10.1038/bmt.2008.295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007359485
    196 https://doi.org/10.1038/bmt.2008.295
    197 rdf:type schema:CreativeWork
    198 sg:pub.10.1038/bmt.2011.192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009911180
    199 https://doi.org/10.1038/bmt.2011.192
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1038/leu.2008.247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016405144
    202 https://doi.org/10.1038/leu.2008.247
    203 rdf:type schema:CreativeWork
    204 sg:pub.10.1038/modpathol.2010.163 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037108867
    205 https://doi.org/10.1038/modpathol.2010.163
    206 rdf:type schema:CreativeWork
    207 sg:pub.10.1038/nm0102-47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018873794
    208 https://doi.org/10.1038/nm0102-47
    209 rdf:type schema:CreativeWork
    210 sg:pub.10.1038/nm1310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006907184
    211 https://doi.org/10.1038/nm1310
    212 rdf:type schema:CreativeWork
    213 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
    214 https://doi.org/10.1038/nrc3239
    215 rdf:type schema:CreativeWork
    216 sg:pub.10.1038/nrc3258 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036173964
    217 https://doi.org/10.1038/nrc3258
    218 rdf:type schema:CreativeWork
    219 sg:pub.10.1038/sj.bmt.1701037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028910700
    220 https://doi.org/10.1038/sj.bmt.1701037
    221 rdf:type schema:CreativeWork
    222 sg:pub.10.1038/sj.bmt.1701546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010266260
    223 https://doi.org/10.1038/sj.bmt.1701546
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1038/sj.bmt.1702187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049549300
    226 https://doi.org/10.1038/sj.bmt.1702187
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.1038/sj.bmt.1702685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020908900
    229 https://doi.org/10.1038/sj.bmt.1702685
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1038/sj.bmt.1703253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039030248
    232 https://doi.org/10.1038/sj.bmt.1703253
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1038/sj.bmt.1704050 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041964316
    235 https://doi.org/10.1038/sj.bmt.1704050
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1038/sj.bmt.1704289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052066147
    238 https://doi.org/10.1038/sj.bmt.1704289
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1038/sj.bmt.1704317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004709499
    241 https://doi.org/10.1038/sj.bmt.1704317
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1038/sj.bmt.1704756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006339769
    244 https://doi.org/10.1038/sj.bmt.1704756
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1038/sj.bmt.1705342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047200252
    247 https://doi.org/10.1038/sj.bmt.1705342
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1038/sj.bmt.1705373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047732682
    250 https://doi.org/10.1038/sj.bmt.1705373
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/sj.leu.2402503 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016584041
    253 https://doi.org/10.1038/sj.leu.2402503
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/sj.leu.2403341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012432553
    256 https://doi.org/10.1038/sj.leu.2403341
    257 rdf:type schema:CreativeWork
    258 grid-institutes:grid.25879.31 schema:alternateName Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    259 schema:name Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    260 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...